Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis Article Swipe
Jean Hoffman‐Censits
,
Marinos Tsiatas
,
Peter Mu‐Hsin Chang
,
Minu Kim
,
L. Antonuzzo
,
Su‐Jin Shin
,
Georgios Gakis
,
Normand Blais
,
Sung Hoon Kim
,
Angela B. Smith
,
Jóse Ángel Arranz Arija
,
Yu‐Li Su
,
Flora Zagouri
,
M. Maruzzo
,
Christophe Tournigand
,
Frédéric Forget
,
A. Schneider
,
Karin Tyroller
,
N. Jacob
,
P. Grivas
,
Begoña P. Valderrama
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.annonc.2025.05.010
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.1016/j.annonc.2025.05.010
Related Topics
Concepts
Javelin
Avelumab
Medicine
Urothelial carcinoma
Interim analysis
Interim
Oncology
Internal medicine
Urology
First line treatment
Metastatic Urothelial Carcinoma
Urothelial cancer
Bladder cancer
Chemotherapy
Immunotherapy
Cancer
Clinical trial
Pembrolizumab
Mechanical engineering
Throwing
Archaeology
Engineering
History
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1016/j.annonc.2025.05.010
- https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029
- OA Status
- bronze
- Cited By
- 2
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4410935761
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4410935761Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1016/j.annonc.2025.05.010Digital Object Identifier
- Title
-
Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysisWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-06-01Full publication date if available
- Authors
-
Jean Hoffman‐Censits, Marinos Tsiatas, Peter Mu‐Hsin Chang, Minu Kim, L. Antonuzzo, Su‐Jin Shin, Georgios Gakis, Normand Blais, Sung Hoon Kim, Angela B. Smith, Jóse Ángel Arranz Arija, Yu‐Li Su, Flora Zagouri, M. Maruzzo, Christophe Tournigand, Frédéric Forget, A. Schneider, Karin Tyroller, N. Jacob, P. Grivas, Begoña P. ValderramaList of authors in order
- Landing page
-
https://doi.org/10.1016/j.annonc.2025.05.010Publisher landing page
- PDF URL
-
https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029Direct OA link when available
- Concepts
-
Javelin, Avelumab, Medicine, Urothelial carcinoma, Interim analysis, Interim, Oncology, Internal medicine, Urology, First line treatment, Metastatic Urothelial Carcinoma, Urothelial cancer, Bladder cancer, Chemotherapy, Immunotherapy, Cancer, Clinical trial, Pembrolizumab, Mechanical engineering, Throwing, Archaeology, Engineering, HistoryTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
2Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2Per-year citation counts (last 5 years)
- References (count)
-
25Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4410935761 |
|---|---|
| doi | https://doi.org/10.1016/j.annonc.2025.05.010 |
| ids.doi | https://doi.org/10.1016/j.annonc.2025.05.010 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40456670 |
| ids.openalex | https://openalex.org/W4410935761 |
| fwci | 13.24276255 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | Q000008 |
| mesh[1].descriptor_ui | D061067 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | administration & dosage |
| mesh[1].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[2].qualifier_ui | Q000009 |
| mesh[2].descriptor_ui | D061067 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | adverse effects |
| mesh[2].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D061067 |
| mesh[3].is_major_topic | True |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[4].qualifier_ui | |
| mesh[4].descriptor_ui | D008297 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | |
| mesh[4].descriptor_name | Male |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D005260 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Female |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000368 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Aged |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D008875 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Middle Aged |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D000971 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[9].qualifier_ui | Q000009 |
| mesh[9].descriptor_ui | D000971 |
| mesh[9].is_major_topic | True |
| mesh[9].qualifier_name | adverse effects |
| mesh[9].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[10].qualifier_ui | Q000008 |
| mesh[10].descriptor_ui | D000971 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | administration & dosage |
| mesh[10].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[11].qualifier_ui | Q000188 |
| mesh[11].descriptor_ui | D001749 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | drug therapy |
| mesh[11].descriptor_name | Urinary Bladder Neoplasms |
| mesh[12].qualifier_ui | Q000473 |
| mesh[12].descriptor_ui | D001749 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | pathology |
| mesh[12].descriptor_name | Urinary Bladder Neoplasms |
| mesh[13].qualifier_ui | Q000401 |
| mesh[13].descriptor_ui | D001749 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | mortality |
| mesh[13].descriptor_name | Urinary Bladder Neoplasms |
| mesh[14].qualifier_ui | Q000031 |
| mesh[14].descriptor_ui | D002166 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | analogs & derivatives |
| mesh[14].descriptor_name | Camptothecin |
| mesh[15].qualifier_ui | Q000008 |
| mesh[15].descriptor_ui | D002166 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | administration & dosage |
| mesh[15].descriptor_name | Camptothecin |
| mesh[16].qualifier_ui | Q000009 |
| mesh[16].descriptor_ui | D002166 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | adverse effects |
| mesh[16].descriptor_name | Camptothecin |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D002166 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Camptothecin |
| mesh[18].qualifier_ui | Q000008 |
| mesh[18].descriptor_ui | D018033 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | administration & dosage |
| mesh[18].descriptor_name | Antibodies, Bispecific |
| mesh[19].qualifier_ui | Q000009 |
| mesh[19].descriptor_ui | D018033 |
| mesh[19].is_major_topic | True |
| mesh[19].qualifier_name | adverse effects |
| mesh[19].descriptor_name | Antibodies, Bispecific |
| mesh[20].qualifier_ui | Q000627 |
| mesh[20].descriptor_ui | D018033 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | therapeutic use |
| mesh[20].descriptor_name | Antibodies, Bispecific |
| mesh[21].qualifier_ui | Q000188 |
| mesh[21].descriptor_ui | D002295 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | drug therapy |
| mesh[21].descriptor_name | Carcinoma, Transitional Cell |
| mesh[22].qualifier_ui | Q000473 |
| mesh[22].descriptor_ui | D002295 |
| mesh[22].is_major_topic | True |
| mesh[22].qualifier_name | pathology |
| mesh[22].descriptor_name | Carcinoma, Transitional Cell |
| mesh[23].qualifier_ui | Q000401 |
| mesh[23].descriptor_ui | D002295 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | mortality |
| mesh[23].descriptor_name | Carcinoma, Transitional Cell |
| mesh[24].qualifier_ui | |
| mesh[24].descriptor_ui | D000077982 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | |
| mesh[24].descriptor_name | Progression-Free Survival |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D000369 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | Aged, 80 and over |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000328 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Adult |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D060046 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | Maintenance Chemotherapy |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D018796 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | Immunoconjugates |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D006801 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Humans |
| mesh[30].qualifier_ui | Q000008 |
| mesh[30].descriptor_ui | D061067 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | administration & dosage |
| mesh[30].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[31].qualifier_ui | Q000009 |
| mesh[31].descriptor_ui | D061067 |
| mesh[31].is_major_topic | True |
| mesh[31].qualifier_name | adverse effects |
| mesh[31].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[32].qualifier_ui | Q000627 |
| mesh[32].descriptor_ui | D061067 |
| mesh[32].is_major_topic | True |
| mesh[32].qualifier_name | therapeutic use |
| mesh[32].descriptor_name | Antibodies, Monoclonal, Humanized |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D008297 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Male |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D005260 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Female |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D000368 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | Aged |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D008875 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Middle Aged |
| mesh[37].qualifier_ui | Q000627 |
| mesh[37].descriptor_ui | D000971 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | therapeutic use |
| mesh[37].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[38].qualifier_ui | Q000009 |
| mesh[38].descriptor_ui | D000971 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | adverse effects |
| mesh[38].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[39].qualifier_ui | Q000008 |
| mesh[39].descriptor_ui | D000971 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | administration & dosage |
| mesh[39].descriptor_name | Antineoplastic Combined Chemotherapy Protocols |
| mesh[40].qualifier_ui | Q000188 |
| mesh[40].descriptor_ui | D001749 |
| mesh[40].is_major_topic | True |
| mesh[40].qualifier_name | drug therapy |
| mesh[40].descriptor_name | Urinary Bladder Neoplasms |
| mesh[41].qualifier_ui | Q000473 |
| mesh[41].descriptor_ui | D001749 |
| mesh[41].is_major_topic | True |
| mesh[41].qualifier_name | pathology |
| mesh[41].descriptor_name | Urinary Bladder Neoplasms |
| mesh[42].qualifier_ui | Q000401 |
| mesh[42].descriptor_ui | D001749 |
| mesh[42].is_major_topic | True |
| mesh[42].qualifier_name | mortality |
| mesh[42].descriptor_name | Urinary Bladder Neoplasms |
| mesh[43].qualifier_ui | Q000031 |
| mesh[43].descriptor_ui | D002166 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | analogs & derivatives |
| mesh[43].descriptor_name | Camptothecin |
| mesh[44].qualifier_ui | Q000008 |
| mesh[44].descriptor_ui | D002166 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | administration & dosage |
| mesh[44].descriptor_name | Camptothecin |
| mesh[45].qualifier_ui | Q000009 |
| mesh[45].descriptor_ui | D002166 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | adverse effects |
| mesh[45].descriptor_name | Camptothecin |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D002166 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Camptothecin |
| mesh[47].qualifier_ui | Q000008 |
| mesh[47].descriptor_ui | D018033 |
| mesh[47].is_major_topic | True |
| mesh[47].qualifier_name | administration & dosage |
| mesh[47].descriptor_name | Antibodies, Bispecific |
| mesh[48].qualifier_ui | Q000009 |
| mesh[48].descriptor_ui | D018033 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | adverse effects |
| mesh[48].descriptor_name | Antibodies, Bispecific |
| mesh[49].qualifier_ui | Q000627 |
| mesh[49].descriptor_ui | D018033 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | therapeutic use |
| mesh[49].descriptor_name | Antibodies, Bispecific |
| type | article |
| title | Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis |
| biblio.issue | 9 |
| biblio.volume | 36 |
| biblio.last_page | 1095 |
| biblio.first_page | 1088 |
| topics[0].id | https://openalex.org/T10458 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2746 |
| topics[0].subfield.display_name | Surgery |
| topics[0].display_name | Bladder and Urothelial Cancer Treatments |
| topics[1].id | https://openalex.org/T12695 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9854000210762024 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2746 |
| topics[1].subfield.display_name | Surgery |
| topics[1].display_name | Urinary and Genital Oncology Studies |
| topics[2].id | https://openalex.org/T12538 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9725000262260437 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Eosinophilic Esophagitis |
| funders[0].id | https://openalex.org/F4320307776 |
| funders[0].ror | https://ror.org/02891sr49 |
| funders[0].display_name | Merck |
| is_xpac | False |
| apc_list.value | 4060 |
| apc_list.currency | USD |
| apc_list.value_usd | 4060 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780548848 |
| concepts[0].level | 3 |
| concepts[0].score | 0.935903787612915 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q2290212 |
| concepts[0].display_name | Javelin |
| concepts[1].id | https://openalex.org/C2777381376 |
| concepts[1].level | 5 |
| concepts[1].score | 0.9327284097671509 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q21083261 |
| concepts[1].display_name | Avelumab |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.9060283899307251 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C3019882237 |
| concepts[3].level | 4 |
| concepts[3].score | 0.6356180906295776 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[3].display_name | Urothelial carcinoma |
| concepts[4].id | https://openalex.org/C61943457 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6313765645027161 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q6046661 |
| concepts[4].display_name | Interim analysis |
| concepts[5].id | https://openalex.org/C2776957806 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6018337607383728 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q4895105 |
| concepts[5].display_name | Interim |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5048330426216125 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.4234519898891449 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C126894567 |
| concepts[8].level | 1 |
| concepts[8].score | 0.422936350107193 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q105650 |
| concepts[8].display_name | Urology |
| concepts[9].id | https://openalex.org/C3017976582 |
| concepts[9].level | 3 |
| concepts[9].score | 0.41487568616867065 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q179661 |
| concepts[9].display_name | First line treatment |
| concepts[10].id | https://openalex.org/C2911057145 |
| concepts[10].level | 5 |
| concepts[10].score | 0.4134834110736847 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[10].display_name | Metastatic Urothelial Carcinoma |
| concepts[11].id | https://openalex.org/C3020745361 |
| concepts[11].level | 4 |
| concepts[11].score | 0.4129686653614044 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[11].display_name | Urothelial cancer |
| concepts[12].id | https://openalex.org/C2780352672 |
| concepts[12].level | 3 |
| concepts[12].score | 0.39731505513191223 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q504775 |
| concepts[12].display_name | Bladder cancer |
| concepts[13].id | https://openalex.org/C2776694085 |
| concepts[13].level | 2 |
| concepts[13].score | 0.22544258832931519 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[13].display_name | Chemotherapy |
| concepts[14].id | https://openalex.org/C2777701055 |
| concepts[14].level | 3 |
| concepts[14].score | 0.19319167733192444 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[14].display_name | Immunotherapy |
| concepts[15].id | https://openalex.org/C121608353 |
| concepts[15].level | 2 |
| concepts[15].score | 0.150516539812088 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[15].display_name | Cancer |
| concepts[16].id | https://openalex.org/C535046627 |
| concepts[16].level | 2 |
| concepts[16].score | 0.09606745839118958 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[16].display_name | Clinical trial |
| concepts[17].id | https://openalex.org/C2780057760 |
| concepts[17].level | 4 |
| concepts[17].score | 0.09446945786476135 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q13896859 |
| concepts[17].display_name | Pembrolizumab |
| concepts[18].id | https://openalex.org/C78519656 |
| concepts[18].level | 1 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q101333 |
| concepts[18].display_name | Mechanical engineering |
| concepts[19].id | https://openalex.org/C207451115 |
| concepts[19].level | 2 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q12898216 |
| concepts[19].display_name | Throwing |
| concepts[20].id | https://openalex.org/C166957645 |
| concepts[20].level | 1 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q23498 |
| concepts[20].display_name | Archaeology |
| concepts[21].id | https://openalex.org/C127413603 |
| concepts[21].level | 0 |
| concepts[21].score | 0.0 |
| concepts[21].wikidata | https://www.wikidata.org/wiki/Q11023 |
| concepts[21].display_name | Engineering |
| concepts[22].id | https://openalex.org/C95457728 |
| concepts[22].level | 0 |
| concepts[22].score | 0.0 |
| concepts[22].wikidata | https://www.wikidata.org/wiki/Q309 |
| concepts[22].display_name | History |
| keywords[0].id | https://openalex.org/keywords/javelin |
| keywords[0].score | 0.935903787612915 |
| keywords[0].display_name | Javelin |
| keywords[1].id | https://openalex.org/keywords/avelumab |
| keywords[1].score | 0.9327284097671509 |
| keywords[1].display_name | Avelumab |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.9060283899307251 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/urothelial-carcinoma |
| keywords[3].score | 0.6356180906295776 |
| keywords[3].display_name | Urothelial carcinoma |
| keywords[4].id | https://openalex.org/keywords/interim-analysis |
| keywords[4].score | 0.6313765645027161 |
| keywords[4].display_name | Interim analysis |
| keywords[5].id | https://openalex.org/keywords/interim |
| keywords[5].score | 0.6018337607383728 |
| keywords[5].display_name | Interim |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.5048330426216125 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.4234519898891449 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/urology |
| keywords[8].score | 0.422936350107193 |
| keywords[8].display_name | Urology |
| keywords[9].id | https://openalex.org/keywords/first-line-treatment |
| keywords[9].score | 0.41487568616867065 |
| keywords[9].display_name | First line treatment |
| keywords[10].id | https://openalex.org/keywords/metastatic-urothelial-carcinoma |
| keywords[10].score | 0.4134834110736847 |
| keywords[10].display_name | Metastatic Urothelial Carcinoma |
| keywords[11].id | https://openalex.org/keywords/urothelial-cancer |
| keywords[11].score | 0.4129686653614044 |
| keywords[11].display_name | Urothelial cancer |
| keywords[12].id | https://openalex.org/keywords/bladder-cancer |
| keywords[12].score | 0.39731505513191223 |
| keywords[12].display_name | Bladder cancer |
| keywords[13].id | https://openalex.org/keywords/chemotherapy |
| keywords[13].score | 0.22544258832931519 |
| keywords[13].display_name | Chemotherapy |
| keywords[14].id | https://openalex.org/keywords/immunotherapy |
| keywords[14].score | 0.19319167733192444 |
| keywords[14].display_name | Immunotherapy |
| keywords[15].id | https://openalex.org/keywords/cancer |
| keywords[15].score | 0.150516539812088 |
| keywords[15].display_name | Cancer |
| keywords[16].id | https://openalex.org/keywords/clinical-trial |
| keywords[16].score | 0.09606745839118958 |
| keywords[16].display_name | Clinical trial |
| keywords[17].id | https://openalex.org/keywords/pembrolizumab |
| keywords[17].score | 0.09446945786476135 |
| keywords[17].display_name | Pembrolizumab |
| language | en |
| locations[0].id | doi:10.1016/j.annonc.2025.05.010 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S41454044 |
| locations[0].source.issn | 0923-7534, 1569-8041 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0923-7534 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Annals of Oncology |
| locations[0].source.host_organization | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_name | Elsevier BV |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320990 |
| locations[0].source.host_organization_lineage_names | Elsevier BV |
| locations[0].license | |
| locations[0].pdf_url | https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Annals of Oncology |
| locations[0].landing_page_url | https://doi.org/10.1016/j.annonc.2025.05.010 |
| locations[1].id | pmid:40456670 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Annals of oncology : official journal of the European Society for Medical Oncology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40456670 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5044979250 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-6970-6509 |
| authorships[0].author.display_name | Jean Hoffman‐Censits |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I145311948, https://openalex.org/I4210164401 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA; Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA. Electronic address: [email protected]. |
| authorships[0].institutions[0].id | https://openalex.org/I145311948 |
| authorships[0].institutions[0].ror | https://ror.org/00za53h95 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I145311948 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Johns Hopkins University |
| authorships[0].institutions[1].id | https://openalex.org/I4210164401 |
| authorships[0].institutions[1].ror | https://ror.org/05m5b8x20 |
| authorships[0].institutions[1].type | facility |
| authorships[0].institutions[1].lineage | https://openalex.org/I2799853436, https://openalex.org/I4210164401 |
| authorships[0].institutions[1].country_code | US |
| authorships[0].institutions[1].display_name | Sidney Kimmel Comprehensive Cancer Center |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | J Hoffman-Censits |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA; Department of Urology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institutions, Baltimore, USA. Electronic address: [email protected]. |
| authorships[1].author.id | https://openalex.org/A5041597500 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-5881-992X |
| authorships[1].author.display_name | Marinos Tsiatas |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1292197403 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Athens Medical Center, Marousi, Greece. |
| authorships[1].institutions[0].id | https://openalex.org/I1292197403 |
| authorships[1].institutions[0].ror | https://ror.org/05azzyk65 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1292197403, https://openalex.org/I4210153954 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Piedmont Athens Regional |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | M Tsiatas |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Medical Oncology, Athens Medical Center, Marousi, Greece. |
| authorships[2].author.id | https://openalex.org/A5088367963 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-1005-6545 |
| authorships[2].author.display_name | Peter Mu‐Hsin Chang |
| authorships[2].countries | TW |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I148366613, https://openalex.org/I2803004286 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Biopharmaceutical Science, National Yang Ming Chiao Tung University, Taipei, Taiwan. |
| authorships[2].institutions[0].id | https://openalex.org/I148366613 |
| authorships[2].institutions[0].ror | https://ror.org/00se2k293 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I148366613 |
| authorships[2].institutions[0].country_code | TW |
| authorships[2].institutions[0].display_name | National Yang Ming Chiao Tung University |
| authorships[2].institutions[1].id | https://openalex.org/I2803004286 |
| authorships[2].institutions[1].ror | https://ror.org/03ymy8z76 |
| authorships[2].institutions[1].type | healthcare |
| authorships[2].institutions[1].lineage | https://openalex.org/I2803004286 |
| authorships[2].institutions[1].country_code | TW |
| authorships[2].institutions[1].display_name | Taipei Veterans General Hospital |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | P M-H Chang |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Biopharmaceutical Science, National Yang Ming Chiao Tung University, Taipei, Taiwan. |
| authorships[3].author.id | https://openalex.org/A5002562810 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-6189-033X |
| authorships[3].author.display_name | Minu Kim |
| authorships[3].countries | KR |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I2802835388 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. |
| authorships[3].institutions[0].id | https://openalex.org/I2802835388 |
| authorships[3].institutions[0].ror | https://ror.org/01z4nnt86 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I2802835388 |
| authorships[3].institutions[0].country_code | KR |
| authorships[3].institutions[0].display_name | Seoul National University Hospital |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | M Kim |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. |
| authorships[4].author.id | https://openalex.org/A5003590471 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | L. Antonuzzo |
| authorships[4].countries | IT |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I45084792 |
| authorships[4].affiliations[0].raw_affiliation_string | Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. |
| authorships[4].institutions[0].id | https://openalex.org/I45084792 |
| authorships[4].institutions[0].ror | https://ror.org/04jr1s763 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I45084792 |
| authorships[4].institutions[0].country_code | IT |
| authorships[4].institutions[0].display_name | University of Florence |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | L Antonuzzo |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Clinical Oncology Unit, Careggi University Hospital, Florence, Italy; Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy. |
| authorships[5].author.id | https://openalex.org/A5085790963 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-9114-8438 |
| authorships[5].author.display_name | Su‐Jin Shin |
| authorships[5].countries | KR |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I193775966 |
| authorships[5].affiliations[0].raw_affiliation_string | Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. |
| authorships[5].institutions[0].id | https://openalex.org/I193775966 |
| authorships[5].institutions[0].ror | https://ror.org/01wjejq96 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I193775966 |
| authorships[5].institutions[0].country_code | KR |
| authorships[5].institutions[0].display_name | Yonsei University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | S J Shin |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. |
| authorships[6].author.id | https://openalex.org/A5080662684 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0995-2406 |
| authorships[6].author.display_name | Georgios Gakis |
| authorships[6].countries | DE |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I68956291 |
| authorships[6].affiliations[0].raw_affiliation_string | University Clinic and Polyclinic of Urology, Martin-Luther-University of Halle-Wittenberg, Halle, Germany. |
| authorships[6].institutions[0].id | https://openalex.org/I68956291 |
| authorships[6].institutions[0].ror | https://ror.org/05gqaka33 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I68956291 |
| authorships[6].institutions[0].country_code | DE |
| authorships[6].institutions[0].display_name | Martin Luther University Halle-Wittenberg |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | G Gakis |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | University Clinic and Polyclinic of Urology, Martin-Luther-University of Halle-Wittenberg, Halle, Germany. |
| authorships[7].author.id | https://openalex.org/A5018835840 |
| authorships[7].author.orcid | https://orcid.org/0000-0003-2698-4362 |
| authorships[7].author.display_name | Normand Blais |
| authorships[7].countries | CA |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210142730, https://openalex.org/I70931966 |
| authorships[7].affiliations[0].raw_affiliation_string | Hematology-Oncology Division, University of Montreal Health Centre (CHUM), Montreal, Canada. |
| authorships[7].institutions[0].id | https://openalex.org/I4210142730 |
| authorships[7].institutions[0].ror | https://ror.org/0410a8y51 |
| authorships[7].institutions[0].type | healthcare |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210142730 |
| authorships[7].institutions[0].country_code | CA |
| authorships[7].institutions[0].display_name | Centre Hospitalier de l’Université de Montréal |
| authorships[7].institutions[1].id | https://openalex.org/I70931966 |
| authorships[7].institutions[1].ror | https://ror.org/0161xgx34 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I70931966 |
| authorships[7].institutions[1].country_code | CA |
| authorships[7].institutions[1].display_name | Université de Montréal |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | N Blais |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Hematology-Oncology Division, University of Montreal Health Centre (CHUM), Montreal, Canada. |
| authorships[8].author.id | https://openalex.org/A5100429359 |
| authorships[8].author.orcid | https://orcid.org/0000-0003-2567-2092 |
| authorships[8].author.display_name | Sung Hoon Kim |
| authorships[8].countries | KR |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I2803058125 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. |
| authorships[8].institutions[0].id | https://openalex.org/I2803058125 |
| authorships[8].institutions[0].ror | https://ror.org/00cb3km46 |
| authorships[8].institutions[0].type | healthcare |
| authorships[8].institutions[0].lineage | https://openalex.org/I2802835388, https://openalex.org/I2803058125 |
| authorships[8].institutions[0].country_code | KR |
| authorships[8].institutions[0].display_name | Seoul National University Bundang Hospital |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | S H Kim |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea. |
| authorships[9].author.id | https://openalex.org/A5013202977 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-3930-9817 |
| authorships[9].author.display_name | Angela B. Smith |
| authorships[9].countries | AU |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I4210140852 |
| authorships[9].affiliations[0].raw_affiliation_string | Icon Cancer Centre, Adelaide, Australia. |
| authorships[9].institutions[0].id | https://openalex.org/I4210140852 |
| authorships[9].institutions[0].ror | https://ror.org/03yg7hz06 |
| authorships[9].institutions[0].type | facility |
| authorships[9].institutions[0].lineage | https://openalex.org/I107656453, https://openalex.org/I170239107, https://openalex.org/I4210140852 |
| authorships[9].institutions[0].country_code | AU |
| authorships[9].institutions[0].display_name | Centre for Cancer Biology |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | A Smith |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Icon Cancer Centre, Adelaide, Australia. |
| authorships[10].author.id | https://openalex.org/A5013608612 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-0009-2147 |
| authorships[10].author.display_name | Jóse Ángel Arranz Arija |
| authorships[10].countries | ES |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I2960094004 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain. |
| authorships[10].institutions[0].id | https://openalex.org/I2960094004 |
| authorships[10].institutions[0].ror | https://ror.org/0111es613 |
| authorships[10].institutions[0].type | healthcare |
| authorships[10].institutions[0].lineage | https://openalex.org/I2960094004, https://openalex.org/I4210139293 |
| authorships[10].institutions[0].country_code | ES |
| authorships[10].institutions[0].display_name | Hospital General Universitario Gregorio Marañón |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | J A Arranz Arija |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain. |
| authorships[11].author.id | https://openalex.org/A5042151733 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-1289-473X |
| authorships[11].author.display_name | Yu‐Li Su |
| authorships[11].countries | TW |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210093821 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Hematology Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. |
| authorships[11].institutions[0].id | https://openalex.org/I4210093821 |
| authorships[11].institutions[0].ror | https://ror.org/00k194y12 |
| authorships[11].institutions[0].type | healthcare |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210093821 |
| authorships[11].institutions[0].country_code | TW |
| authorships[11].institutions[0].display_name | Kaohsiung Chang Gung Memorial Hospital |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Y L Su |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Hematology Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan. |
| authorships[12].author.id | https://openalex.org/A5046758725 |
| authorships[12].author.orcid | https://orcid.org/0000-0001-7153-6556 |
| authorships[12].author.display_name | Flora Zagouri |
| authorships[12].countries | GR |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210113950 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Clinical Therapeutics, 'Alexandra' General Hospital of Athens, Athens, Greece. |
| authorships[12].institutions[0].id | https://openalex.org/I4210113950 |
| authorships[12].institutions[0].ror | https://ror.org/029hept94 |
| authorships[12].institutions[0].type | healthcare |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210113950 |
| authorships[12].institutions[0].country_code | GR |
| authorships[12].institutions[0].display_name | Alexandra Hospital |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | F Zagouri |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Clinical Therapeutics, 'Alexandra' General Hospital of Athens, Athens, Greece. |
| authorships[13].author.id | https://openalex.org/A5056738756 |
| authorships[13].author.orcid | |
| authorships[13].author.display_name | M. Maruzzo |
| authorships[13].countries | IT |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210109345, https://openalex.org/I4210153126 |
| authorships[13].affiliations[0].raw_affiliation_string | Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. |
| authorships[13].institutions[0].id | https://openalex.org/I4210153126 |
| authorships[13].institutions[0].ror | https://ror.org/04tfzc498 |
| authorships[13].institutions[0].type | healthcare |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210153126 |
| authorships[13].institutions[0].country_code | IT |
| authorships[13].institutions[0].display_name | Istituti di Ricovero e Cura a Carattere Scientifico |
| authorships[13].institutions[1].id | https://openalex.org/I4210109345 |
| authorships[13].institutions[1].ror | https://ror.org/01xcjmy57 |
| authorships[13].institutions[1].type | healthcare |
| authorships[13].institutions[1].lineage | https://openalex.org/I4210109345, https://openalex.org/I4210153126 |
| authorships[13].institutions[1].country_code | IT |
| authorships[13].institutions[1].display_name | Istituto Oncologico Veneto |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | M Maruzzo |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Istituto Oncologico Veneto IOV - IRCCS, Padova, Italy. |
| authorships[14].author.id | https://openalex.org/A5020893157 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-6232-4815 |
| authorships[14].author.display_name | Christophe Tournigand |
| authorships[14].countries | FR |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210097159 |
| authorships[14].affiliations[0].raw_affiliation_string | Department of Medical Oncology, AP-HP, Hôpital Henri Mondor, Créteil, France. |
| authorships[14].institutions[0].id | https://openalex.org/I4210097159 |
| authorships[14].institutions[0].ror | https://ror.org/00pg5jh14 |
| authorships[14].institutions[0].type | healthcare |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210097159 |
| authorships[14].institutions[0].country_code | FR |
| authorships[14].institutions[0].display_name | Assistance Publique – Hôpitaux de Paris |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | C Tournigand |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Department of Medical Oncology, AP-HP, Hôpital Henri Mondor, Créteil, France. |
| authorships[15].author.id | https://openalex.org/A5109889220 |
| authorships[15].author.orcid | |
| authorships[15].author.display_name | Frédéric Forget |
| authorships[15].affiliations[0].raw_affiliation_string | Centre Hospitalier de l'Ardenne, Libramont-Chevigny, Belgium. |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | F Forget |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Centre Hospitalier de l'Ardenne, Libramont-Chevigny, Belgium. |
| authorships[16].author.id | https://openalex.org/A5050872014 |
| authorships[16].author.orcid | |
| authorships[16].author.display_name | A. Schneider |
| authorships[16].countries | DE |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I164928964 |
| authorships[16].affiliations[0].raw_affiliation_string | Merck Healthcare KGaA, Darmstadt, Germany. |
| authorships[16].institutions[0].id | https://openalex.org/I164928964 |
| authorships[16].institutions[0].ror | https://ror.org/04b2dty93 |
| authorships[16].institutions[0].type | company |
| authorships[16].institutions[0].lineage | https://openalex.org/I164928964 |
| authorships[16].institutions[0].country_code | DE |
| authorships[16].institutions[0].display_name | Merck (Germany) |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | A Schneider |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Merck Healthcare KGaA, Darmstadt, Germany. |
| authorships[17].author.id | https://openalex.org/A5067797812 |
| authorships[17].author.orcid | |
| authorships[17].author.display_name | Karin Tyroller |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210098679, https://openalex.org/I4210118097 |
| authorships[17].affiliations[0].raw_affiliation_string | EMD Serono Research & Development Institute, Inc., Billerica, USA, an affiliate of Merck KGaA. |
| authorships[17].institutions[0].id | https://openalex.org/I4210098679 |
| authorships[17].institutions[0].ror | https://ror.org/010xeam31 |
| authorships[17].institutions[0].type | company |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210098679, https://openalex.org/I4210112155 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Ono Pharmaceutical (United States) |
| authorships[17].institutions[1].id | https://openalex.org/I4210118097 |
| authorships[17].institutions[1].ror | https://ror.org/01r8yv121 |
| authorships[17].institutions[1].type | other |
| authorships[17].institutions[1].lineage | https://openalex.org/I4210118097 |
| authorships[17].institutions[1].country_code | US |
| authorships[17].institutions[1].display_name | Research & Development Institute |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | K Tyroller |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | EMD Serono Research & Development Institute, Inc., Billerica, USA, an affiliate of Merck KGaA. |
| authorships[18].author.id | https://openalex.org/A5071033640 |
| authorships[18].author.orcid | |
| authorships[18].author.display_name | N. Jacob |
| authorships[18].countries | DE |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I164928964 |
| authorships[18].affiliations[0].raw_affiliation_string | Merck Healthcare KGaA, Darmstadt, Germany. |
| authorships[18].institutions[0].id | https://openalex.org/I164928964 |
| authorships[18].institutions[0].ror | https://ror.org/04b2dty93 |
| authorships[18].institutions[0].type | company |
| authorships[18].institutions[0].lineage | https://openalex.org/I164928964 |
| authorships[18].institutions[0].country_code | DE |
| authorships[18].institutions[0].display_name | Merck (Germany) |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | N Jacob |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Merck Healthcare KGaA, Darmstadt, Germany. |
| authorships[19].author.id | https://openalex.org/A5035248125 |
| authorships[19].author.orcid | |
| authorships[19].author.display_name | P. Grivas |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I201448701, https://openalex.org/I4210089486, https://openalex.org/I58610484 |
| authorships[19].affiliations[0].raw_affiliation_string | University of Washington, Fred Hutchinson Cancer Center, Seattle, USA. |
| authorships[19].institutions[0].id | https://openalex.org/I4210089486 |
| authorships[19].institutions[0].ror | https://ror.org/007ps6h72 |
| authorships[19].institutions[0].type | nonprofit |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210089486 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Fred Hutch Cancer Center |
| authorships[19].institutions[1].id | https://openalex.org/I58610484 |
| authorships[19].institutions[1].ror | https://ror.org/02jqc0m91 |
| authorships[19].institutions[1].type | education |
| authorships[19].institutions[1].lineage | https://openalex.org/I58610484 |
| authorships[19].institutions[1].country_code | US |
| authorships[19].institutions[1].display_name | Seattle University |
| authorships[19].institutions[2].id | https://openalex.org/I201448701 |
| authorships[19].institutions[2].ror | https://ror.org/00cvxb145 |
| authorships[19].institutions[2].type | education |
| authorships[19].institutions[2].lineage | https://openalex.org/I201448701 |
| authorships[19].institutions[2].country_code | US |
| authorships[19].institutions[2].display_name | University of Washington |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | P Grivas |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | University of Washington, Fred Hutchinson Cancer Center, Seattle, USA. |
| authorships[20].author.id | https://openalex.org/A5048855238 |
| authorships[20].author.orcid | https://orcid.org/0000-0003-0175-1263 |
| authorships[20].author.display_name | Begoña P. Valderrama |
| authorships[20].countries | ES |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210153139 |
| authorships[20].affiliations[0].raw_affiliation_string | Hospital Universitario Virgen del Rocio, Seville, Spain. |
| authorships[20].institutions[0].id | https://openalex.org/I4210153139 |
| authorships[20].institutions[0].ror | https://ror.org/04vfhnm78 |
| authorships[20].institutions[0].type | healthcare |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210153139 |
| authorships[20].institutions[0].country_code | ES |
| authorships[20].institutions[0].display_name | Hospital Universitario Virgen del Rocío |
| authorships[20].author_position | last |
| authorships[20].raw_author_name | B P Valderrama |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Hospital Universitario Virgen del Rocio, Seville, Spain. |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029 |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10458 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2746 |
| primary_topic.subfield.display_name | Surgery |
| primary_topic.display_name | Bladder and Urothelial Cancer Treatments |
| related_works | https://openalex.org/W4232051653, https://openalex.org/W4200128746, https://openalex.org/W4396852850, https://openalex.org/W4400115189, https://openalex.org/W2559306776, https://openalex.org/W4399976475, https://openalex.org/W4400567337, https://openalex.org/W4367296748, https://openalex.org/W4399394208, https://openalex.org/W4296767555 |
| cited_by_count | 2 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| locations_count | 2 |
| best_oa_location.id | doi:10.1016/j.annonc.2025.05.010 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S41454044 |
| best_oa_location.source.issn | 0923-7534, 1569-8041 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0923-7534 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Annals of Oncology |
| best_oa_location.source.host_organization | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_name | Elsevier BV |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| best_oa_location.source.host_organization_lineage_names | Elsevier BV |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Annals of Oncology |
| best_oa_location.landing_page_url | https://doi.org/10.1016/j.annonc.2025.05.010 |
| primary_location.id | doi:10.1016/j.annonc.2025.05.010 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S41454044 |
| primary_location.source.issn | 0923-7534, 1569-8041 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0923-7534 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Annals of Oncology |
| primary_location.source.host_organization | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_name | Elsevier BV |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320990 |
| primary_location.source.host_organization_lineage_names | Elsevier BV |
| primary_location.license | |
| primary_location.pdf_url | https://www.annalsofoncology.org/action/showPdf?pii=S0923753425002029 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Annals of Oncology |
| primary_location.landing_page_url | https://doi.org/10.1016/j.annonc.2025.05.010 |
| publication_date | 2025-06-01 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4366339435, https://openalex.org/W3087464965, https://openalex.org/W4281848279, https://openalex.org/W4410038451, https://openalex.org/W4200026971, https://openalex.org/W4392769651, https://openalex.org/W3209393335, https://openalex.org/W4391130564, https://openalex.org/W4386466678, https://openalex.org/W2036193982, https://openalex.org/W6669868243, https://openalex.org/W6871777368, https://openalex.org/W4403500663, https://openalex.org/W4403670091, https://openalex.org/W4402922390, https://openalex.org/W6869301594, https://openalex.org/W6877804583, https://openalex.org/W4401875183, https://openalex.org/W4404426832, https://openalex.org/W4407386155, https://openalex.org/W4390991030, https://openalex.org/W4399394202, https://openalex.org/W2077189932, https://openalex.org/W4402274740, https://openalex.org/W4407700589 |
| referenced_works_count | 25 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 95 |
| countries_distinct_count | 10 |
| institutions_distinct_count | 21 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.44999998807907104 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.96299374 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |